There is a clinical need to investigate and optimize the benefits of novel oral combination therapies, not only as asthma treatment but also to address the unsatisfied need to simultaneously treat the entire airway (for example, the upper and lower airways: rhinitis and asthma) with a single therapy. Because asthma and rhinitis are caused by multiple and similar mediators, clinical benefit will accrue incrementally by testing combinations that make biological and clinical sense. Because compliance is believed to be superior with oral therapy,1 such combinations increasingly will be tested.